Key Considerations for Disease-Modifying Parkinson’s Disease Trials
Taking into consideration the lessons learned from Alzheimer’s disease studies could benefit the design of neuro-protective studies.
The importance of the patient voice in the rare disease market
Orphan drugs, by nature, remain commercially underdeveloped, and as demand in the market increases, patients in clinical trials need to be considered.
Adoptive Cellular Transfer (ACT): Novel Cancer Trials Demand That Participating Sites Act Differently
Sites participating in ACT trials need to be prepared with regulatory intelligence, scalable logistics, adequate resources and dedicated data management teams.
Alzheimer’s in Clinical Trials
Attempting to develop casual treatment against the progression of Alzheimer’s disease has resulted in unparalleled series of failures for nearly 2 decades of drug development.
Oncology Clinical Trials in Asia Pacific
The size and significance of the APAC market make clinical trials, on the cutting edge of oncology development, an attractive investment.
Generating RWE to maximise revenue in biotech trials
As more RWE is generated within the biotech industry, a strategic plan is necessary to maximise revenue.
Alexa… What’s the deal with voice assistants?
As the buzz around voice technology increases, our digital team is asked more & more, “What’s the deal with voice assistants? Can we offer this to our clients?”
The Long Journey towards Patient Centricity
Various regulatory efforts have been implemented in the last 25-30 years to include the patients’ perspective into drug development.
Insights from Inside the Jury Room: 2019 Medical, Marketing & Media (MM&M) Awards
Read our latest blog post to access insights from inside the 2019 Medical Marketing & Media (MM&M) Awards jury room.
Patient Centricity in Oncology Trials
Adopting patient-centric elements into oncology clinical trials has the potential to significantly impact patient recruitment and retention.
Pharma Marketing in the Digital Age
Social media and digital technology are providing new opportunities for marketers by facilitating direct interaction with patients and care partners.
Connecting with the Patient for Better Insights
Getting more connected with the patient and easing their burden is really making a difference to enrollment rates.
The Need for New Business Models under MDR/IVDR
The new MDR/IVDR will go into effect in 2020, greatly increasing the complexity of keeping existing products on the market and introducing new ones.
5 Applications of AI to Enhance RWE Generation
Exploring machine learning and natural language processing to maximize RWE output using advanced computing.
EMA Publishes Second Draft Guideline on New MDR Rules Specifying Quality Requirements for Drug-Device Combinations
Key takeaways from the EMA’s second draft guidance on MDR and its impact on combination products.
Tackling RWE Challenges to Demonstrate Healthcare Value
Despite multiple challenges, RWE clearly has huge potential to inform healthcare stakeholders.
Towards a Data-Driven Feasibility Assessment
Explore how conducting a thorough data-driven feasibility assessment sets sponsors up for success in the operational aspects of their trials.
The Digitization of Clinical Drug Development
ICON expert Dr. Uma Arumugam takes a look at the advancements in digital applications and technology impacting clinical drug development.
Biosimilar Development in Ophthalmology
ICON experts Bart Chapman and Shanthi Sundaramoorthy answer common questions about ophthalmology studies, and those relating to biosimilars.
Using Economic Models to Gain Early Access
Early access schemes demand new ways of performing health economic evaluations.